Abstract
Since cell-free DNA (cfDNA) fragments of placental origin can be isolated and analyzed from the blood of pregnant women. Applications of this finding have been developed and implemented in clinical care pathways worldwide at an unprecedented pace and manner. Implementation patterns, however, exhibit considerable insufficiencies. Different “motors” of implementation processes, like the market or various regulatory institutions, can be identified at a national level. Each “motor” entails characteristic ethical challenges which are exemplified impressively by a rising number of case reports.
Empirical data demonstrate that there are significant “losses” in the respective translational processes, especially when the results from clinical research are to be translated into the clinical reality of NIPT (the so called “second roadblock” (T2)). These “losses” are perceived in the fields of knowledge transfer, professional standardization and ethical debate. Recommendations of professional organizations often fail to reach general practitioners. Blindsided by the new diagnostic procedure in their clinical practice, professionals in prenatal care express their insecurities with regard to its handling. Ethical debate appears to adhere to pre-existing (and partly already proven to be insufficient) normative frameworks for prenatal testing. While all of these deficits are typical for the implementation processes of many new molecular diagnostic procedures, especially in NIPT, they show a high variability between different nations.
A critical assessment of the preferred strategy of implementation against the background of already existing national ethical frameworks is indispensable, if potential adverse effects are to be diminished. The described translational losses seem to be significantly reducible by granting the translational process in roadblock T2 more time.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Allyse M, Minear MA, Berson E et al (2015) Non-invasive prenatal testing: a review of international implementation and challenges. Int J Womens Health 7:113–126
Bianchi DW, Wilkins-Haug L (2014) Integration of noninvasive DNA testing for aneuploidy into prenatal care: what has happened since the rubber met the road? Clin Chem 60:78–87
Bianchi DW, Chudova D, Sehnert AJ et al (2015) Noninvasive prenatal testing and incidental detection of occult maternal malignancies. JAMA 314:162–169
Butler D (2008) Translational research: crossing the valley of death. Nature 453:840–842
Chandrasekharan S, Minear MA, Hung A et al (2014) Noninvasive prenatal testing goes global. Sci Transl Med 6:231fs15
Dar P, Curnow KJ, Gross SJ et al (2014) Clinical experience and follow-up with large scale single-nucleotide polymorphism-based noninvasive prenatal aneuploidy testing. Am J Obstet Gynecol 211:527 e1-527 e17
De Jong A, Dondorp WJ, De Die-Smulders CE et al (2010) Non-invasive prenatal testing: ethical issues explored. Eur J Hum Genet 18:272–277
Everett TR, Chitty LS (2015) Cell-free fetal DNA: the new tool in fetal medicine. Ultrasound Obstet Gynecol 45:499–507
Fan HC, Blumenfeld YJ, Chitkara U et al (2008) Noninvasive diagnosis of fetal aneuploidy by shotgun sequencing DNA from maternal blood. Proc Natl Acad Sci USA 105:16266–16271
Haymon L, Simi E, Moyer K et al (2014) Clinical implementation of noninvasive prenatal testing among maternal fetal medicine specialists. Prenat Diagn 34:416–423
Hill M, Wright D, Daley R et al (2014) Evaluation of non-invasive prenatal testing (NIPT) for aneuploidy in an NHS setting: a reliable accurate prenatal non-invasive diagnosis (RAPID) protocol. BMC Pregnancy Childbirth 14:229
Lo YM, Chui RW (2008) Noninvasive prenatal diagnosis of fetal chromosomal aneuploidies by maternal plasma nucleic acid analysis. Clin Chem 54:461–466
Lo YM, Corbetta N, Chamberlain PF et al (1997) Presence of fetal DNA in maternal plasma and serum. The Lancet 350:485–487
Schwartz K, Vilquin JT (2003) Building the translational highway: toward new partnerships between academia and the private sector. Nat Med 9:493–495
Sung NS, Crowley WF Jr, Genel M et al (2000) Central challenges facing the national clinical research enterprise. JAMA 289:1278–1287
Van Schendel RV, Dondorp WJ, Timmermans DR et al (2015) NIPT-based screening for Down syndrome and beyond: what do pregnant women think? Prenat Diagn 35(6):598–604
Verweij EJ, De Boer MA, Oepkes D (2014) Non-invasive prenatal testing for trisomy 13: more harm than good? Ultrasound Obstet Gynecol 44:112–114
Warsof SL, Larion S, Abuhamad AZ (2015) Overview of the impact of noninvasive prenatal testing on diagnostic procedures. Prenat Diagn 35(10):972–979. doi:10.1002/pd.4601
Woolf SH (2008) The meaning of translational research and why it matters. JAMA 299:211–213
Acknowledgements
The research in this paper was funded by The German Federal Ministry of Education and Research (BMBF) within the ELSA funding initiative (fund number 01GP1201).
Conflict of Interest
No conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer International Publishing Switzerland
About this paper
Cite this paper
Schmitz, D. (2016). Lost in Translation? Ethical Challenges of Implementing a New Diagnostic Procedure. In: Gahan, P., Fleischhacker, M., Schmidt, B. (eds) Circulating Nucleic Acids in Serum and Plasma – CNAPS IX. Advances in Experimental Medicine and Biology, vol 924. Springer, Cham. https://doi.org/10.1007/978-3-319-42044-8_35
Download citation
DOI: https://doi.org/10.1007/978-3-319-42044-8_35
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-42042-4
Online ISBN: 978-3-319-42044-8
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)